CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Nivolumab 240mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04197310
NCT04197310Phase 2Completed
CompareCT.gov

Phase II Trial of Cabozantinib in Combination With Nivolumab for Advanced Carcinoid Tumors

Dana-Farber Cancer Institute·interventional·Posted Dec 13, 2019·Updated Jan 31, 2025

In Brief

A Phase 2 clinical trial evaluating Nivolumab and Cabozantinib for Carcinoid Tumor and 2 related conditions. Completed, enrolled 19 participants across 2 sites.

Detailed Summary

This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. \- Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Exelixis

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 13, 2019
Enrollment StartDec 26, 2019
Primary CompletionDec 27, 2023
Study CompletionJan 31, 2024
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 6.6 years ago

Interventions

Nivolumabdrug

240mg, intravenously, Day 1 and 15 of a 28 day cycle

Cabozantinibdrug

40mg, orally, Daily for a 28 day cycle